Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
This compounded oral formulation is designed to leverage similar pathways that may help support appetite regulation, satiety, and overall weight-related goals under the guidance of a licensed healthcare provider
Without eating disorder screening, a prescriber may see a patient in a higher-weight body and recommend a GLP-1 medication without any awareness that they are treating someone in the midst of a life-threatening restrictive illness
M.AguilaM
The system contains ingredients with plausible mechanisms for modestly supporting GLP-1 production, particularly berberine and resistant starch
Findings Participants and Intervention: Between October 5, 2018, and February 1, 2019, 304 individuals were randomly assigned to either receive semaglutide 2.4 mg (n = 152) or placebo (n = 152) and were encompassed in the comprehensive analysis set (comprising all randomized individuals as per the intention-to-treat principle)
Withdrawals due to AEs were 7% versus 3% (PC), NNH = 25
